氯沙坦对法洛四联症修复术后右心室功能障碍的影响:REDEFINE随机双盲试验
REDEFINE试验为多中心、前瞻性、1:1随机、双盲、安慰剂对照研究,纳入95例法洛四联症修复术后伴右心室射血分数<50%且无严重瓣膜功能障碍的成人,随机接受氯沙坦150mg每日或安慰剂治疗18-24个月。结果显示氯沙坦未显著改善右心室射血分数(+0.51%;95%CI -1.0至+2.0;P=0.50),次要终点亦无显著差异。事后分析提示在非限制性右心室且不完全重构亚组中氯沙坦可能改善右心室射血分数(+2.7%;95%CI +0.1至+5.4;P=0.045)。
要点
- 氯沙坦150mg每日治疗18-24个月未显著改善法洛四联症修复术后右心室射血分数。
- 左心室射血分数、峰值有氧运动能力和NT-proBNP等次要终点均无显著治疗效应(P>0.30)。
- 事后分析提示非限制性右心室伴不完全重构亚组可能获益,但需未来更大样本研究验证。
核心结论
- 氯沙坦对法洛四联症修复术后右心室功能障碍及次要终点参数无显著影响。
- 事后分析提示氯沙坦可能对特定脆弱亚组(非限制性右心室且不完全重构)有改善右心室射血分数的作用。
研究设计与样本
- REDEFINE试验为研究者发起的多中心、前瞻性、1:1随机、双盲、安慰剂对照研究。
- 纳入95例法洛四联症修复术后伴右心室射血分数<50%且无严重瓣膜功能障碍的成人。
- 患者随机接受氯沙坦150mg每日(47例)或安慰剂(48例),目标治疗时长18-24个月。
- 主要结局为意向性治疗分析中通过心血管磁共振测定的右心室射血分数变化。
主要发现
- 氯沙坦组(n=42)右心室射血分数从44.4±5.1%变为45.2±5.0%,安慰剂组(n=46)从43.2±6.3%变为43.6±6.9%。
- 氯沙坦与安慰剂相比右心室射血分数改善无统计学意义(+0.51%;95%CI -1.0至+2.0;P=0.50)。
- 左心室射血分数、峰值有氧运动能力和N末端脑钠肽前体等次要结局均无显著治疗效应(P>0.30)。
- 预设亚组分析中,氯沙坦对有症状、限制性右心室、右心室射血分数<40%、肺动脉瓣置换或QRS碎裂等亚组的右心室射血分数无统计学显著影响。
- 事后分析显示,在非限制性右心室且不完全重构(QRS碎裂和既往肺动脉瓣置换)亚组(n=30)中,氯沙坦与右心室射血分数改善相关(+2.7%;95%CI +0.1至+5.4;P=0.045)。
临床怎么用
- 不推荐常规使用氯沙坦150mg每日来改善法洛四联症修复术后成人右心室功能障碍。
- 对非限制性右心室且不完全重构的特定亚组,氯沙坦的潜在获益尚需未来更大规模研究确认。
局限性
- 事后亚组分析样本量小(n=30),结果需谨慎解读。
- 研究结论可能不适用于严重瓣膜功能障碍或右心室射血分数≥50%的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The effect of angiotensin II receptor blockers on right ventricular (RV) function is still unknown. Angiotensin II receptor blockers are beneficial in patients with acquired left ventricular dysfunction, and recent findings have suggested a favorable effect in symptomatic patients with systemic RV dysfunction. The current study aimed to determine the effect of losartan, an angiotensin II receptor blocker, on subpulmonary RV dysfunction in adults after repaired tetralogy of Fallot. METHODS: The REDEFINE trial (Right Ventricular Dysfunction in Tetralogy of Fallot: Inhibition of the Renin-Angiotensin-Aldosterone System) is an investigator-initiated, multicenter, prospective, 1:1 randomized, double-blind, placebo-controlled study. Adults with repaired tetralogy of Fallot and RV dysfunction (RV ejection fraction [EF] <50%) but without severe valvular dysfunction were eligible. Patients were randomly assigned between losartan (150 mg daily) and placebo with target treatment duration between 18 and 24 months. The primary outcome was RV EF change, determined by cardiovascular MRI in intention-to-treat analysis. RESULTS: Of 95 included patients, 47 patients received 150 mg losartan daily (age, 38.0±12.4 years; 74% male), and 48 patients received placebo (age, 40.6±11.4 years; 63% male). Overall, RV EF did not change in patients allocated to losartan (n=42) (44.4±5.1% to 45.2±5.0%) and placebo (n=46) (43.2±6.3% to 43.6±6.9%). Losartan did not significantly improve RV EF in comparison with placebo (+0.51%; 95% confidence interval, -1.0 to +2.0; P=0.50). No significant treatment effects were found on secondary outcomes: left ventricular EF, peak aerobic exercise capacity, and N-terminal pro-brain natriuretic peptide (P>0.30 for all). In predefined subgroup analyses, losartan did not have a statistically significant impact on RV EF in subgroups with symptoms, restrictive RV, RV EF<40%, pulmonary valve replacement, or QRS fragmentation. However, in a post hoc analysis, losartan was associated with improved RV EF in a subgroup (n=30) with nonrestrictive RV and incomplete remodeling (QRS fragmentation and previous pulmonary valve replacement) (+2.7%; 95% confidence interval, +0.1 to +5.4; P=0.045). CONCLUSIONS: Losartan had no significant effect on RV dysfunction or secondary outcome parameters in repaired tetralogy of Fallot. Future larger studies may determine whether there might be a role for losartan in specific vulnerable subgroups. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. Unique identifier: NCT02010905.
引用
- Bokma JP, Winter MM, van Dijk AP, et al. Effect of Losartan on Right Ventricular Dysfunction: Results From the Double-Blind, Randomized REDEFINE Trial (Right Ventricular Dysfunction in Tetralogy of Fallot: Inhibition of the Renin-Angiotensin-Aldosterone System) in Adults With Repaired Tetralogy of Fallot. Circulation. 2017. PMID: 29222139. doi:10.1161/CIRCULATIONAHA.117.031438
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。